Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Bayer holds off on break-up to focus on management revamp for now -sources

Published 01/18/2024, 08:10 AM
Updated 01/18/2024, 09:16 AM
© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen, Germany February 27, 2019. REUTERS/Wolfgang Rattay/File Photo

By Ludwig Burger, Emma-Victoria Farr and Patricia Weiss

(Reuters) -Bayer AG will likely hold off on presenting break-up plans at an investor update scheduled for early March as CEO Bill Anderson prefers to focus on an internal reorganisation for now, two people familiar with the matter told Reuters on Thursday.

The likely delay in preparations to separate Bayer (OTC:BAYRY)'s pharmaceuticals, consumer health and agriculture units comes even after several investors have for years urged the company to split up to shed a conglomerate discount.

Anderson, at the helm since June last year, said in November he is weighing options to break apart the diversified company in a staggered fashion but would not rule out keeping all businesses.

He also said at the time that he would seek to speed up decision-making by cutting a significant number of management positions, confirming an earlier Reuters report.

The sources said on Thursday that plans for any break-up could still be announced at a later stage, but that internal trimming would take precedence for now.

Bayer declined to comment on the deliberations, which were first reported by Bloomberg.

Late on Wednesday, the company said it had agreed with shop stewards on a significant reduction in managerial jobs and extended a pact that rules out compulsory redundancies in Germany until the end of 2026.

The diversified group is weighed down by the risk of further costly U.S. litigation over an alleged cancer-causing effect of its best-selling weedkiller Roundup, and by a weak agriculture business.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

In a further blow, Bayer in November stopped a major trial testing a new anti-blood-clotting drug due to a lack of efficacy, throwing its most promising development project into doubt.

Bayer shares fell 2.5% by 1318 GMT. Portfolio manager Markus Manns at Union Investment said he would still want to see a critical review of the company structure at the March 5 capital markets day.

That should come on top of an update on how to reduce litigation risks, cut debt, boost the cash flow and drug development pipeline.

"This can't happen all at once but the overall direction and urgency needs to be the right one," Manns said.

Analysts at brokerage Stifel wrote in a note last week, however, that the current weakness in operating earnings and break-up costs would leave little room for investors to appreciate any separation scenarios.

"While we consider the CEO's task to change the company's culture as important, it is probably not a short-term driver for the stock," the analysts said.

(Additional Reporting by Urvi Dugar in Bengaluru; Editing by Devika Syamnath, Miranda Murray and Susan Fenton)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.